Exicure Inc (XCUR) - Total Liabilities
Based on the latest financial reports, Exicure Inc (XCUR) has total liabilities worth $10.66 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore XCUR net assets growth trend to track the company's year-over-year net asset growth rate.
Exicure Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Exicure Inc's total liabilities have evolved over time, based on quarterly financial data. See XCUR cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Exicure Inc Competitors by Total Liabilities
The table below lists competitors of Exicure Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Erria A/S
CO:ERRIA
|
Denmark | Dkr68.77 Million |
|
Inventure Growth & Securities Limited
NSE:INVENTURE
|
India | Rs1.00 Billion |
|
GULLBERG+JANSSON AB
F:9D7
|
Germany | €121.61 Million |
|
Rigsave S.P.A.
XETRA:H68
|
USA | €51.93 Million |
|
In8bio Inc
NASDAQ:INAB
|
USA | $3.48 Million |
|
Globe Textiles (India) Limited
NSE:GLOBE
|
India | Rs2.77 Billion |
|
REC Silicon ASA
OL:RECSI
|
Norway | Nkr582.30 Million |
|
Reliance Home Finance Limited
NSE:RHFL
|
India | Rs117.00 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Exicure Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Exicure Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Exicure Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Exicure Inc (2015–2025)
The table below shows the annual total liabilities of Exicure Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.12 Million | +22.10% |
| 2024-12-31 | $8.28 Million | -3.10% |
| 2023-12-31 | $8.55 Million | +1.70% |
| 2022-12-31 | $8.41 Million | -84.33% |
| 2021-12-31 | $53.64 Million | +37.75% |
| 2020-12-31 | $38.94 Million | +12.81% |
| 2019-12-31 | $34.52 Million | +342.29% |
| 2018-12-31 | $7.80 Million | -13.40% |
| 2017-12-31 | $9.01 Million | -50.29% |
| 2016-12-31 | $18.13 Million | +1203.24% |
| 2015-12-31 | $1.39 Million | -- |
About Exicure Inc
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood Ci… Read more